問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間：2023-09-19

蔡政軒
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

61Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡政軒

List

80Cases

2025-09-01 - 2028-09-30

Phase I

Active
An open-label, multicenter, phase I trial was conducted to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of ALPS12 in patients with metastatic small cell lung cancer.

  • Condition/Disease

    Part 1: Dose Escalation Section ⚫ Incidence, nature, and severity of adverse events (AEs) (according to NCI CTCAE v.5.0 grading), CRS and immune effector cell-related neurotoxic syndromes (ICANS) are graded according to the ASTCT consensus grading criteria. ⚫ Nature and frequency of dose-limiting toxicities (DLT), AEs, PK, and pharmacodynamic properties. ⚫ Serum ALPS12 concentrations and their PK parameters, including maximum serum concentration (Cmax) and area under the plasma concentration-time curve (AUC). ⚫ Incidence of ALPS12 anti-antibody (ADA) and its impact on ALPS12 exposure. Part 2: Extended Section ⚫ Objective response, defined as a confirmed complete response (CR) or partial response (PR) conforming to RECIST v.1.1, as determined by the trial administrator. ⚫ Incidence, nature, and severity of AEs (according to NCI CTCAE v.5.0 grading), CRS and ICANS are graded according to the ASTCT consensus grading criteria. Consensus grading standard grading

  • Test Drug

    ALPS12 Gazyva

Participate Sites
5Sites

Recruiting5Sites

2024-09-24 - 2029-12-31

Phase II

Active
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Anvumetostat in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    MTAP-deleted NSCLC

  • Test Drug

    Tablets

Participate Sites
3Sites

Recruiting3Sites

2025-02-01 - 2030-12-31

Active
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    Tablets; Hard capsules

Participate Sites
4Sites

Recruiting4Sites

2025-09-22 - 2029-03-18

Active
The master plan for an open-label, multi-drug, multicenter, phase II trial evaluates the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity (LIBRA) of a novel combination therapy in participants with locally advanced or metastatic non-small cell lung cancer.

  • Condition/Disease

    • Safety: Number of participants experiencing adverse events (AEs) and serious adverse events (SAEs). • Efficacy: Objective response rate (ORR).

  • Test Drug

    Dato-DXd Rilvegostomig Xinruize

Participate Sites
9Sites

Recruiting9Sites

2025-09-01 - 2035-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    Tablets; Subcutaneous injections

Participate Sites
6Sites

Recruiting6Sites

2025-09-30 - 2033-12-31

Phase II

Active
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

  • Condition/Disease

    Squamous Non-small Cell Lung Cancer

  • Test Drug

    Injectables

Participate Sites
6Sites

Recruiting6Sites

2025-10-09 - 2033-12-31

Phase I/II

Active
A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer

  • Condition/Disease

    Small Cell Lung Cancer

  • Test Drug

    Injectables

Participate Sites
2Sites

Recruiting2Sites

2021-12-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-03-01 - 2027-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2024-07-15 - 2026-08-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB